title: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
authors.forename: David
authors.initials: D
authors.lastname: End
authors.forename: Arturo
authors.initials: A
authors.lastname: Molina
authors.forename: Mary
authors.initials: M
authors.lastname: Todd
authors.forename: Michael L
authors.initials: ML
authors.lastname: Meyers
mesh_terms: D000737:Androstenols / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives*; D011239:Prednisolone / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D011944:Receptors, Androgen / Q000235:genetics*; D013148:Spironolactone / Q000031:analogs & derivatives*
chemical_list: D000737:Androstenols; D011944:Receptors, Androgen; D010669:Phenylthiohydantoin; D013148:Spironolactone; D011239:Prednisolone